Compare Public Storage (PSA) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Public Storage vs Viatris Inc — how do they compare? Public Storage trades at $286.29 (market cap $53.35B), while Viatris Inc trades at $17.63 (market cap $20.03B). The key difference: Public Storage is far larger — about 2.7× Viatris Inc's market cap, and Public Storage pays the higher dividend (4.2%). Which is the better fit depends on your goals — on Pluang, investors hold Public Storage for 130 Days and Viatris Inc for 57 Days on average.
| PSA | VTRS | |
|---|---|---|
Market Cap | $53.35B | $20.03B |
Volume | 1,176,034 | 14,109,977 |
Sector | Real Estate | Health |
52-Week High | $330.47 | $18.27 |
52-Week Low | $258.44 | $9.74 |
Typical Hold Time | 130 Days | 57 Days |
Enterprise Value | $67.62B | $32.15B |
Dividend Yield | 4.2% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Public Storage (PSA) trades at $287.72, up 2.03% today, with a bearish technical signal but strong fundamentals including a 41.8% net income margin and consistent earnings beats. The stock faces resistance near $288, with support at $282. Recent developments include the completion of the Public Storage Canada acquisition and a $400 million senior notes offering in the Canadian market, signaling expansion efforts.
The outlook is mixed: analyst consensus targets $328.33 (14% upside), but technicals and some news highlight valuation concerns. Key risks include interest rate sensitivity and competitive pressures in the REIT sector. Earnings momentum and a 4.05% yield offer support, though investor caution is warranted amid bearish indicators.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
